Rat brain myo-inositol 3-phosphate synthase is a phosphoprotein.

The therapeutic effects of lithium in bipolar disorder are poorly understood. Lithium decreases free inositol levels by inhibiting inositol monophosphatase 1 and myo-inositol 3-phosphate synthase (IPS). In this study, we demonstrate for the first time that IPS can be phosphorylated. This was evident when purified rat IPS was dephosphorylated by lambda protein phosphatase and analyzed by phospho-specific ProQ-Diamond staining and Western blot analysis. These techniques demonstrated a mobility shift consistent with IPS being phosphorylated. Mass spectral analysis revealed that Serine-524 (S524), which resides in the hinge region derived from exon 11 of the gene, is the site for phosphorylation. Further, an antibody generated against a synthetic peptide of IPS containing monophosphorylated-S524, was able to discriminate the phosphorylated and non-phosphorylated forms of IPS. The phosphoprotein is found in the brain and testis, but not in the intestine. The intestinal IPS isoform lacks the peptide bearing S524, and hence, cannot be phosphorylated. Evidences suggest that IPS is monophosphorylated at S524 and that the removal of this phosphate does not alter its enzymatic activity. These observations suggest a novel function for IPS in brain and other tissues. Future studies should resolve the functional role of phospho-IPS in brain inositol signaling.

Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells.

The mechanisms underlying lithium's therapeutic efficacy in the chronic treatment of bipolar disorder are not clearly understood. Useful insights can be obtained by identifying genes that are differentially regulated during chronic lithium treatment. Toward this end, we have used microarray technology to identify mRNAs that are differentially expressed in a human neuronal cell line that has been continuously maintained in therapeutic levels of lithium for 33 days. Significantly, unlike other transcriptomes where predominantly rodent cells were used and a limited number of genes probed, we have used human cells probed with more extensive 44,000 gene microarrays. A total of 671 differentially regulated transcripts, after correcting for false discovery rates, were identified, of which 347 and 324, respectively, were found to be up- and downregulated. Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated, implying a beneficial effect of lithium on neuronal cells. Several of the most highly regulated genes are novel, uncharacterized and encode proteins of unknown function. Differentially expressed genes associated with phosphoinositide metabolism include those encoding phosphatidyl inositol 4-phosphate 5-kinase type II alpha (PIP5K2A), WD repeat domain, phosphoinositide interacting 1 protein (WIPI49), tribbles homolog 3 (TRB3) and sorting nexin 14 (SNX14). A protein interactome using some of the saliently regulated genes identified protein kinase C (PKC) as a major target for lithium action while a global analysis of all 671 differentially expressed genes identified the mitogen-activated protein kinase pathway as the most regulated. The list of highly regulated genes, besides encoding putative targets for antimanic agents, should prove useful in defining novel pathways, or to better understand the mechanisms, underlying the mood stabilization process.

Protection from ischemic cell death by the induction of cytoglobin.

Methods to reduce beta-cell loss after islet isolation and transplantation must be developed if islet transplantation is to become a preferred treatment for diabetes. Most recent research has focused on the reduction of toxicity from immunosuppressants and the enhancement of revascularization by growth factors such as vascular endothelial growth factor. Cytoglobin is an intracellular oxygen-binding protein found in islet beta-cells, inducible by hypoxia. It is our hypothesis that cytoglobin induction and overexpression may improve survival and function of transplanted islets by preventing ischemic cell death. Lewis rat islets and MIN6 cells were transfected with the cytoglobin gene. Control and transfected cells and islets were held for 4 hours at 20% oxygen before glucose challenge. Another group of islets and cells was held for 4 hours at 20% and then 1% oxygen prior to glucose challenge. Untreated or transfected Lewis rat islets (n = 800) were transplanted beneath the renal capsule of streptozotocin diabetic Lewis rats. In another study, Sprague-Dawley islets were transfected and transplanted into streptozotocin diabetic Lewis rats. Fasting blood glucose was used as an indicator of islet function and survival. Cytoglobin transfected islets and cells retained the ability to secrete insulin at low oxygen concentrations in contrast to controls. Cytoglobin over expression reduced the development of central islet necrosis after 5 days in tissue culture. Cytoglobin inhibited the onset of immunorejection (14 +/- 2 days) as compared with controls islets (5 +/- 2 days). Cytoglobin induction may be a useful adjunct to islet transplantation.